14th Drug Discovery for Neurodegeneration Workshop

A Virtual Course on Translating Research into Novel Drug Targets


Virtual, April 27-May 11, 2020

Due to the COVID-19 pandemic, the Drug Discovery for Neurodegeneration Workshop was held as a virtual meeting.

Access to the sessions, recordings, slides and Q&As remains possible through the free registration.

Throughout April and May, we will release a series of webinars on developing drugs for neurodegenerative diseases including Alzheimer’s, Parkinson’s, Huntington’s disease, amyotrophic lateral sclerosis, frontotemporal degeneration and multiple sclerosis.

Presentations from internationally recognized leaders in neuroscience will share their experiences from different stages of the drug discovery pipeline, from target identification to clinical trials and more!

  • Academia 47% 47%
  • Industry 33% 33%
  • Non-profit 13% 13%
  • Government 3% 3%
  • Consulting 3% 3%
  • Other 1% 1%

Data from 2019 Workshop

%

Percentage of attendees selecting quality of the meeting as "Excellent" and "Very Good"

OBJECTIVES

  • Train a cadre of interdisciplinary scientists in the principles of drug discovery for neurodegenerative disease.
  • Provide a platform to exchange ideas, knowledge and resources about drug discovery for neurodegenerative disease.
  • Stimulate pre-clinical research in the discovery and testing of novel compounds aimed at the prevention and treatment of neurodegenerative disease.
  • Build public-private partnerships that will accelerate drug discovery for neurodegenerative disease.

BENEFITS FOR PARTICIPANTS

  • Gain an understanding of the drug discovery pipeline, from target identification to clinical trials
  • Learn from case studies and challenges associated with developing drugs for neurodegenerative diseases
  • Attend panel discussions to learn about careers outside academia
  • Attend panel discussions to learn about relevant grant opportunities and how to get funded

SPEAKERS and CHAIRS

Joseph Araujo
InterVivo Solutions

Kurt Brunden
Univ. of Pennsylvania

Charles Cywin
NIH/NINDS

Kuldip Dave
The ALS Assoc.

Philip De Jager
Columbia Univ.

Anita DiFrancesco
Samumed

Maria Emanuel
Univ. of NH

Jacques Galipeau
Univ. of Wisconsin

John Gerdes
Rio Pharma

Edmund Graziani
Apertor Labs

David Kemp
Cure PSP

James Kirkland
Mayo Clinic

Walter Kostich
Natl. MS Society

Douglas Macdonald
CHDI Foundation

Zane Martin
NIH/NIA

Liliana Menalled
MJFF

Kenneth Olivier
Olivier KOnsulting

Natasha Penner
Biogen

Allen Reitz
ALS Biopharma

Edward Spack
Vector BioSol./Therini

Nadine Tatton
The AFTD

Leticia Toledo-Sherman
Rainwater Fdtion

Ishu Venkataraman
Euroimmun

D. Martin Watterson
Northwestern Univ.

Maurice Zauderer
Vaccinex

SPONSORS